Clinical Trial Record

Return to Clinical Trials

Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction


2019-05-31


2020-02-08


2020-09-28


92

Study Overview

Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction

The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with pancreatic carcinoma and biliary obstruction who are treated by stent insertion with or without high-intensity focused ultrasound ablation.

Distal malignant biliary obstruction is a common problem in patients with pancreatic carcinoma. In unresectable pancreatic carcinomas, percutaneous stent placement has been pivotal in providing relief from obstructive jaundice, improving the quality of life, and allowing the maintenance of anticancer treatment. Venous chemotherapy, transcatheter arterial chemoembolization, or radiotherapy have been used to prolong stent patency and survival after stent insertion for patients with pancreatic carcinoma and biliary obstruction. High-intensity focused ultrasound ablation is a noninvasive and atoxic treatment of malignant tumor using focused ultrasound energy from an extracorporeal source that is targeted within the body resulting in thermally induced necrosis and apoptosis. The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with pancreatic carcinoma and biliary obstruction who are treated by stent insertion with or without high-intensity focused ultrasound ablation.

  • Pancreatic Carcinoma
  • Biliary Obstruction
  • DEVICE: biliary stent and high-intensity focused ultrasound ablation system
  • DEVICE: biliary stent
  • 20190522-021

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2019-05-22  

N/A  

2020-09-28  

2019-05-22  

N/A  

2020-09-30  

2019-05-24  

N/A  

2020-09  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Stent with high-intensity focused ultrasound ablation

Patients undergo stent insertion with high-intensity focused ultrasound ablation on day 1.

DEVICE: biliary stent and high-intensity focused ultrasound ablation system

  • Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
ACTIVE_COMPARATOR: Stent without high-intensity focused ultrasound ablation

Patients undergo stent insertion on day 1.

DEVICE: biliary stent

  • Self-expandable biliary nitinol alloys stent
Primary Outcome MeasuresMeasure DescriptionTime Frame
6-month survival rateFrom the date of randomization until the date of first documented death from any cause.From the date of randomization until the date of first documented death from any cause, assessed up to 12 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Stent patencyStent dysfunction is suspected when the patient experiences recurrence of jaundice.From the date of randomization until the date of first documented stent dysfunction, assessed up to 10 months
Stent dysfunction free survivalFrom the date of randomization until the date of first documented stent dysfunction or the date of death from any cause, whichever came first.From the date of randomization until the date of first documented stent dysfunction or the date of death from any cause, whichever came first, assessed up to 10 months.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. malignant distal biliary obstruction; 2. pathologically diagnosed pancreatic carcinoma; 3. unresectable cases.
    Exclusion Criteria:
    1. inability to obtain informed consent; 2. Eastern Cooperative Oncology Group performance status of 4; 3. life expectancy of 3 months or less; 4. biliary obstruction that was not directly caused by pancreatic carcinoma.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Chi Cao, MD, Xuzhou Central Hospital

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    • Niu S, Cheng L, Qiao Y, Fu YF, Cao C. Combined Stent Insertion and High-intensity Focused Ultrasound Ablation for Patients With Malignant Obstructive Jaundice. Surg Laparosc Endosc Percutan Tech. 2016 Dec;26(6):488-492. doi: 10.1097/SLE.0000000000000327.
    • Zhang FQ, Li L, Huang PC, Xia FF, Zhu L, Cao C. Stent Insertion With High Intensity-Focused Ultrasound Ablation for Biliary Obstruction Caused by Pancreatic Carcinoma: A Randomized Controlled Trial. Surg Laparosc Endosc Percutan Tech. 2021 Feb 17;31(3):298-303. doi: 10.1097/SLE.0000000000000918.